BARRX deal saves Curon from Nasdaq delisting
This article was originally published in Clinica
Executive Summary
Curon Medical, the Fremont, California company specialising in gastrointestinal disorders, has averted a potential delisting from the US Nasdaq stock market after the firm succeeded in clinching a patent deal with BARRX Medical.